Humacyte announced positive interim results from its V012 Phase 3 study showing its acellular tissue engineered vessel (ATEV) significantly increased catheter-free days by an average of 91 days compared to the standard autologous arteriovenous (AV) fistula in female dialysis patients. This improvement reduces infection risks and dialysis complications, addressing a critical need for better vascular access in women with end-stage kidney disease. Following these results, the trial enrollment will stop early, and Humacyte plans to file a supplemental Biologic License Application with the FDA in the second half of 2026. The ATEV offers a promising off-the-shelf solution that could improve patient outcomes and reduce healthcare costs associated with dialysis.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
